This document provides methods and materials related to assessing responsiveness to lenalidomide thalidomide and/or other IMiDs (structural and functional analogues of thalidomide that represent a promising new class of immunomodulators). For example methods and materials for using CRBN levels to determine whether or not cancer cells (e.g. multiple myeloma cells) are susceptible to lenalidomide thalidomide and/or other IMiDs are provided.

暂无附图